key: cord-0908068-houj55im
authors: Mieler, William F.
title: Editorial on Treat-and-Extend Regimens for the Management of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations from the Asia-Pacific Vitreo-retina Society
date: 2021-11-16
journal: Asia Pac J Ophthalmol (Phila)
DOI: 10.1097/apo.0000000000000454
sha: 8065c357ab334cbb8fbdfc1bbd5dbf306018902a
doc_id: 908068
cord_uid: houj55im

nan

have used different criteria to define disease activity (amount of subretinal and/or intraretinal fluid, timeframe to accumulation of such fluid, etc), and have had differing timeframes for follow-up evaluations. The authors of this review have not attempted to indicate if there is any difference in treatment outcomes based on the specific anti-VEGF agent which had been employed in the nAMD studies. Also, there is no level 1 data as to recommendations of how or when to proceed with treatment or monitoring beyond the 12-to 16-week T&E interval timeframe. The authors do suggest that perhaps with two 16-week timeframes and no disease activity, treatment could be indefinitely suspended, albeit with continued monitoring. The role of photodynamic therapy (PDT), especially in the setting of PCV, perhaps may still need to be integrated into treatment regimens, at least on occasion. Finally, the recent (and still ongoing) COVID-19 pandemic has made studies challenging in terms of missed appointments and follow-up examinations, which has potentially altered clinical trial results.

In summary, it is important to keep in mind that once one has decided to employ T&E guidelines in the management of nAMD and PCV, these are generalized recommendations. Still, these recommendations seem very reasonable and well thought out, at least for the majority of patients. It is also important to keep in mind that new treatment modalities currently in the pipeline (port delivery system, gene therapy, new therapeutic drugs, impact of home monitoring OCT devices, etc) 7 will hopefully offer even more effective treatment and outcomes in the future, perhaps being more cost-effective as well. Once again, I commend the authors for undertaking this complex and fascinating study.

Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence

ASRS Preferences and Trends Membership Survey

American Society of Retina Specialists

Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study

Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treatand-extend analysis trial with ranibizumab study

Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial

Efficacy of intravitreal aflibercept administered using treat-and-extend regimen over 2 years in patients with neovascular age-related macular degeneration: 1-year ARIES results

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020